Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation

J Dermatol Sci. 2018 Sep;91(3):276-284. doi: 10.1016/j.jdermsci.2018.05.009. Epub 2018 May 29.

Abstract

Background: Psoriasis is a systemic inflammatory disease with dramatic responses to TNF-α inhibitors. TNF-α is mainly produced by macrophages. However, how macrophage polarization contributes to psoriasis remains unknown.

Objective: We aimed to investigate the molecular mechanisms of macrophage polarization in psoriasis.

Methods: 8 patients with moderate to severe psoriasis (Male/Female: 4/4, average age: 47.9 years old) and 8 healthy controls (Male/Female: 4/4, average age: 49.3 years old) were recruited. Their peripheral CD14+ monocytes were isolated with magnetic beads and then were differentiated into macrophages. The differential macrophage polarization was compared among normal controls, psoriatic patients before and after TNF-α inhibitors. The U937 cells were used to investigate the mechanisms by which TNF-α altered the macrophage polarization.

Results: The ratio of M1 to M2a macrophage polarization was higher in psoriatic patients comparing with that in controls. The decreasing M1/M2a ratio was parallel to decreasing PASI severity score after adalimumab treatment. Consistently, TNF-α blockage decreased M1/M2a ratio in U937 cells. The induction of STAT1 and IRF-1 in polarized U937 M1 cells was inhibited by TNF-α inhibitor. However, STAT1 and/or IRF-1 interference could not resume M1 polarization. In skin, the increased M1 and M2 infiltration in lesions returned to baseline after successful treatment with TNF-α inhibitor.

Conclusions: Increased M1 polarization is associated with higher disease severity in psoriasis, resuming to baseline after successful treatment by TNF-α inhibitors. TNF-α blockage inhibits M1 polarization through STAT1- and IRF-1-independent pathways. Macrophage polarization may contribute to disease progression in psoriasis.

Keywords: IRF-1; Macrophage polarization; Psoriasis; STAT1; TNF-α inhibitor.

MeSH terms

  • Adalimumab / therapeutic use*
  • Adult
  • Anti-Inflammatory Agents / therapeutic use*
  • Case-Control Studies
  • Cell Plasticity / drug effects*
  • Female
  • Humans
  • Interferon Regulatory Factor-1 / metabolism*
  • Macrophages / drug effects*
  • Macrophages / immunology
  • Macrophages / metabolism
  • Male
  • Middle Aged
  • Monocytes / drug effects*
  • Monocytes / immunology
  • Monocytes / metabolism
  • Phenotype
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Psoriasis / metabolism
  • STAT1 Transcription Factor / metabolism*
  • Severity of Illness Index
  • Signal Transduction / drug effects
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / immunology
  • Tumor Necrosis Factor-alpha / metabolism
  • U937 Cells

Substances

  • Anti-Inflammatory Agents
  • IRF1 protein, human
  • Interferon Regulatory Factor-1
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • Tumor Necrosis Factor-alpha
  • Adalimumab